Details of the Drug

General Information of Drug (ID: DMZOLBI)

Drug Name
Carbamazepine
Synonyms Carbamazepine (iv, epilepsy); Carbamazepine (iv, epilepsy), Lundbeck; Carbamazepine (iv, epilepsy), Ovation Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1], [2]
Type-1 diabetes 5A10 NDA filed [3]
Gastric adenocarcinoma 2B72 Phase 3 [4]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 236.27
Topological Polar Surface Area (xlogp) 2.5
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.9 +/- 0.3 mg/L [5]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 19 +/- 7 h [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [6]
Bioavailability
The bioavailability of drug is 75-85% [5]
Clearance
The apparent oral clearance of drug is 25 +/- 5 mL/min [7]
Elimination
After an oral dose of radiolabeled carbamazepine, 72% of the administered radioactive dose was detected in the urine and the remainder of the ingested dose was found in the feces [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 35 - 40 hours [7]
Metabolism
The drug is metabolized via the liver [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 113.00359 micromolar/kg/day [9]
Vd
The volume of distribution (Vd) of drug is 1.0 L/kg [10]
Water Solubility
The ability of drug to dissolve in water is measured as 0.256 mg/mL [6]
Chemical Identifiers
Formula
C15H12N2O
IUPAC Name
benzo[b][1]benzazepine-11-carboxamide
Canonical SMILES
C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
InChI
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
InChIKey
FFGPTBGBLSHEPO-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2554
ChEBI ID
CHEBI:3387
CAS Number
298-46-4
DrugBank ID
DB00564
TTD ID
D04MSM
VARIDT ID
DR00395
INTEDE ID
DR0270
ACDINA ID
D00097

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Modulator [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [15]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [16]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [18]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [19]
Epoxide hydrolase 1 (EPHX1) DELB4KP HYEP_HUMAN Substrate [20]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Carbamazepine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Primidone DM0WX6I Moderate Increased metabolism of Carbamazepine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [94]
Felbamate DM1V5ZS Moderate Decreased metabolism of Carbamazepine caused by Felbamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Carbamazepine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [96]
Ethosuximide DMDZ9LT Minor Increased metabolism of Carbamazepine caused by Ethosuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Cenobamate DMGOVHA Moderate Increased metabolism of Carbamazepine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [98]
Tiagabine DMKSQG0 Moderate Increased metabolism of Carbamazepine caused by Tiagabine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [99]
Stiripentol DMMSDOY Major Increased metabolism of Carbamazepine caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [100]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Carbamazepine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Brivaracetam DMSEPK8 Moderate Increased metabolism of Carbamazepine caused by Brivaracetam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Clonazepam DMTO13J Moderate Increased metabolism of Carbamazepine caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [102]
Ethotoin DMXWOCP Moderate Increased metabolism of Carbamazepine caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [101]
Phenobarbital DMXZOCG Minor Increased metabolism of Carbamazepine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [103]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Carbamazepine caused by Eslicarbazepine mediated induction of UGT. Epilepsy/seizure [8A61-8A6Z] [104]
⏷ Show the Full List of 13 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Carbamazepine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Accelerated clearance of Carbamazepine due to the transporter induction by Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [102]
Clindamycin DM15HL8 Moderate Increased metabolism of Carbamazepine caused by Clindamycin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [105]
Nicotinamide DMUPE07 Minor Decreased metabolism of Carbamazepine caused by Nicotinamide mediated inhibition of CYP450 enzyme. Acquired cutaneous blood vessel malformation [EF20] [106]
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Carbamazepine and Methylene blue. Acquired methaemoglobinaemia [3A93] [107]
Repaglinide DM5SXUV Moderate Increased metabolism of Carbamazepine caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [108]
Pioglitazone DMKJ485 Moderate Increased metabolism of Carbamazepine caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [109]
Ivosidenib DM8S6T7 Major Increased metabolism of Carbamazepine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [110]
Midostaurin DMI6E0R Major Increased metabolism of Carbamazepine caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [111]
Gilteritinib DMWQ4MZ Major Increased metabolism of Carbamazepine caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [112]
Emapalumab DMZG5WL Moderate Altered metabolism of Carbamazepine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [102]
Galantamine DMEO794 Moderate Antagonize the effect of Carbamazepine when combined with Galantamine. Alzheimer disease [8A20] [113]
Donepezil DMIYG7Z Moderate Antagonize the effect of Carbamazepine when combined with Donepezil. Alzheimer disease [8A20] [113]
Siltuximab DMGEATB Moderate Altered metabolism of Carbamazepine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [102]
Ivabradine DM0L594 Major Increased metabolism of Carbamazepine caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [102]
Bepridil DM0RKS4 Major Increased metabolism of Carbamazepine caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [114]
Dronedarone DMA8FS5 Moderate Increased metabolism of Carbamazepine caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [115]
Nifedipine DMSVOZT Major Increased metabolism of Carbamazepine caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [114]
Bedaquiline DM3906J Major Increased metabolism of Carbamazepine caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [102]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Carbamazepine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [116]
Halazepam DMPFWO6 Moderate Increased metabolism of Carbamazepine caused by Halazepam mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [117]
Voriconazole DMAOL2S Major Increased metabolism of Carbamazepine caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [118]
Posaconazole DMUL5EW Moderate Increased metabolism of Carbamazepine caused by Posaconazole mediated induction of UGT. Aspergillosis [1F20] [102]
Aminophylline DML2NIB Moderate Increased metabolism of Carbamazepine caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [119]
Roflumilast DMPGHY8 Moderate Increased metabolism of Carbamazepine caused by Roflumilast mediated induction of CYP450 enzyme. Asthma [CA23] [120]
Desipramine DMT2FDC Moderate Antagonize the effect of Carbamazepine when combined with Desipramine. Attention deficit hyperactivity disorder [6A05] [121]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Carbamazepine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [122]
Clarithromycin DM4M1SG Major Decreased metabolism of Carbamazepine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [123]
Linezolid DMGFPU2 Major Additive serotonergic effects by the combination of Carbamazepine and Linezolid. Bacterial infection [1A00-1C4Z] [107]
Telithromycin DMZ4P3A Major Increased metabolism of Carbamazepine caused by Telithromycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [102]
Retigabine DMGNYIH Moderate Increased metabolism of Carbamazepine caused by Retigabine mediated induction of UGT. Behcet disease [4A62] [124]
Cariprazine DMJYDVK Moderate Increased metabolism of Carbamazepine caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [125]
Erdafitinib DMI782S Major Increased metabolism of Carbamazepine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [126]
Pexidartinib DMS2J0Z Major Decreased metabolism of Carbamazepine caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [127]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Carbamazepine caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [128]
Lapatinib DM3BH1Y Moderate Increased metabolism of Carbamazepine caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [129]
HKI-272 DM6QOVN Major Increased metabolism of Carbamazepine caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [129]
LY2835219 DM93VBZ Major Increased metabolism of Carbamazepine caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [130]
Exemestane DM9HPW3 Moderate Increased metabolism of Carbamazepine caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [131]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Carbamazepine caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [132]
Tucatinib DMBESUA Major Increased metabolism of Carbamazepine caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [133]
Palbociclib DMD7L94 Major Increased metabolism of Carbamazepine caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [129]
Alpelisib DMEXMYK Major Increased metabolism of Carbamazepine caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [134]
Thiotepa DMIZKOP Moderate Increased metabolism of Carbamazepine caused by Thiotepa mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [135]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Carbamazepine caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [132]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Carbamazepine caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [136]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Carbamazepine caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [137]
Bosutinib DMTI8YE Major Increased metabolism of Carbamazepine caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [138]
Estradiol DMUNTE3 Moderate Increased metabolism of Carbamazepine caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [132]
Atorvastatin DMF28YC Moderate Increased metabolism of Carbamazepine caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [139]
Macitentan DMP79A1 Major Increased metabolism of Carbamazepine caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [140]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Carbamazepine caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [141]
Corticotropin DMP9TWZ Moderate Increased metabolism of Carbamazepine caused by Corticotropin mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [142]
PF-04449913 DMSB068 Major Increased metabolism of Carbamazepine caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [143]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Carbamazepine caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [144]
Anisindione DM2C48U Moderate Increased metabolism of Carbamazepine caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [145]
Regorafenib DMHSY1I Moderate Increased metabolism of Carbamazepine caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [146]
Irinotecan DMP6SC2 Major Increased metabolism of Carbamazepine caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [147]
Intedanib DMSTA36 Major Increased metabolism of Carbamazepine caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [148]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Carbamazepine and Olopatadine. Conjunctiva disorder [9A60] [149]
Drospirenone DM1A9W3 Major Increased metabolism of Carbamazepine caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [132]
Levonorgestrel DM1DP7T Major Increased metabolism of Carbamazepine caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [132]
Ulipristal DMBNI20 Moderate Increased metabolism of Carbamazepine caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [102]
Norgestimate DMYP4XC Major Increased metabolism of Carbamazepine caused by Norgestimate mediated induction of CYP450 enzyme. Contraceptive management [QA21] [150]
Levobupivacaine DM783CH Minor Increased metabolism of Carbamazepine caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [151]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Carbamazepine caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [119]
Mifepristone DMGZQEF Moderate Increased metabolism of Carbamazepine caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [152]
Osilodrostat DMIJC9X Major Increased metabolism of Carbamazepine caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [102]
Ivacaftor DMZC1HS Major Increased metabolism of Carbamazepine caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [129]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Carbamazepine and Ethanol. Cystitis [GC00] [149]
MK-8228 DMOB58Q Moderate Accelerated clearance of Carbamazepine due to the transporter induction by MK-8228. Cytomegaloviral disease [1D82] [129]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Carbamazepine caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [118]
Aprepitant DM053KT Moderate Increased metabolism of Carbamazepine caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [153]
Sertraline DM0FB1J Moderate Increased risk of lowers seizure threshold by the combination of Carbamazepine and Sertraline. Depression [6A70-6A7Z] [102]
Vilazodone DM4LECQ Moderate Increased metabolism of Carbamazepine caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [154]
Nefazodone DM4ZS8M Major Decreased metabolism of Carbamazepine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [155]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Carbamazepine and Selegiline. Depression [6A70-6A7Z] [107]
Vortioxetine DM6F1PU Moderate Increased metabolism of Carbamazepine caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [156]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Carbamazepine and Isocarboxazid. Depression [6A70-6A7Z] [107]
Escitalopram DMFK9HG Minor Increased metabolism of Carbamazepine caused by Escitalopram mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [157]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Carbamazepine and Tranylcypromine. Depression [6A70-6A7Z] [107]
OPC-34712 DMHG57U Moderate Increased metabolism of Carbamazepine caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [158]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Carbamazepine and Phenelzine. Depression [6A70-6A7Z] [107]
Clomipramine DMINRKW Moderate Antagonize the effect of Carbamazepine when combined with Clomipramine. Depression [6A70-6A7Z] [121]
Trazodone DMK1GBJ Moderate Increased metabolism of Carbamazepine caused by Trazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [159]
Doxepin DMPI98T Moderate Increased metabolism of Carbamazepine caused by Doxepin mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [121]
Empagliflozin DMRF9YK Moderate Increased metabolism of Carbamazepine caused by Empagliflozin mediated induction of UGT. Diabetes mellitus [5A10] [129]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Carbamazepine caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [129]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Carbamazepine caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [160]
Ospemifene DMC4GEI Moderate Increased metabolism of Carbamazepine caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [161]
Ingrezza DMVPLNC Major Increased metabolism of Carbamazepine caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [162]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Carbamazepine caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [150]
Cannabidiol DM0659E Moderate Increased metabolism of Carbamazepine caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [102]
Ethacrynic acid DM60QMR Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Ethacrynic acid. Essential hypertension [BA00] [163]
Nicardipine DMCDYW7 Major Increased metabolism of Carbamazepine caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [114]
Praziquantel DMOU1PK Major Increased metabolism of Carbamazepine caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [164]
Bay 80-6946 DMLOS5R Major Accelerated clearance of Carbamazepine due to the transporter induction by Bay 80-6946. Follicular lymphoma [2A80] [165]
Tazemetostat DMWP1BH Major Increased metabolism of Carbamazepine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [166]
Mirabegron DMS1GYT Minor Increased metabolism of Carbamazepine caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [167]
Itraconazole DMCR1MV Moderate Increased metabolism of Carbamazepine caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [168]
Miconazole DMPMYE8 Moderate Decreased metabolism of Carbamazepine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [102]
Ripretinib DM958QB Major Increased metabolism of Carbamazepine caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [169]
Sunitinib DMCBJSR Major Increased metabolism of Carbamazepine caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [129]
Avapritinib DMK2GZX Major Increased metabolism of Carbamazepine caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [102]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Carbamazepine caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [103]
Ergotamine DMKR3C5 Moderate Increased metabolism of Carbamazepine caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [129]
Eplerenone DMF0NQR Minor Increased metabolism of Carbamazepine caused by Eplerenone mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [170]
Chlorothiazide DMLHESP Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Chlorothiazide. Heart failure [BD10-BD1Z] [171]
Furosemide DMMQ8ZG Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Furosemide. Heart failure [BD10-BD1Z] [171]
Amiloride DMRTSGP Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Amiloride. Heart failure [BD10-BD1Z] [171]
Bumetanide DMRV7H0 Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Bumetanide. Heart failure [BD10-BD1Z] [171]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [171]
Boceprevir DMBSHMF Major Increased metabolism of Carbamazepine caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [172]
PSI-7977 DMLSUWZ Major Accelerated clearance of Carbamazepine due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [102]
Simeprevir DMLUA9D Major Increased metabolism of Carbamazepine caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [173]
Telaprevir DMMRV29 Major Increased metabolism of Carbamazepine caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [174]
ABT-267 DMNQ869 Major Increased metabolism of Carbamazepine caused by ABT-267 mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [102]
Daclatasvir DMSFK9V Major Increased metabolism of Carbamazepine caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [102]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Carbamazepine caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [175]
Rifampin DMA8J1G Moderate Increased metabolism of Carbamazepine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [176]
Pretomanid DMDYA31 Major Increased metabolism of Carbamazepine caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [177]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Carbamazepine and Procarbazine. Hodgkin lymphoma [2B30] [107]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Carbamazepine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [178]
MK-1439 DM215WE Major Increased metabolism of Carbamazepine caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [179]
Delavirdine DM3NF5G Major Increased metabolism of Carbamazepine caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [180]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Carbamazepine caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [181]
Cobicistat DM6L4H2 Major Increased metabolism of Carbamazepine caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [129]
Tipranavir DM8HJX6 Moderate Increased metabolism of Carbamazepine caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [181]
Efavirenz DMC0GSJ Moderate Increased metabolism of Carbamazepine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [182]
Dolutegravir DMCZGRE Major Increased metabolism of Carbamazepine caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [129]
Saquinavir DMG814N Moderate Increased metabolism of Carbamazepine caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [181]
Elvitegravir DMG9B1U Major Increased metabolism of Carbamazepine caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [129]
Etravirine DMGV8QU Major Increased metabolism of Carbamazepine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [183]
Lopinavir DMITQS0 Major Increased metabolism of Carbamazepine caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [184]
Rilpivirine DMJ0QOW Major Increased metabolism of Carbamazepine caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [185]
Amprenavir DMLMXE0 Moderate Increased metabolism of Carbamazepine caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [181]
Darunavir DMN3GCH Major Increased metabolism of Carbamazepine caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [118]
Atazanavir DMSYRBX Moderate Increased metabolism of Carbamazepine caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [181]
Maraviroc DMTL94F Major Increased metabolism of Carbamazepine caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [186]
Raltegravir DMYURI6 Minor Increased metabolism of Carbamazepine caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [118]
Simvastatin DM30SGU Moderate Increased metabolism of Carbamazepine caused by Simvastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [187]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Carbamazepine and Mipomersen. Hyper-lipoproteinaemia [5C80] [188]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Carbamazepine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [118]
Paricalcitol DMYBV3G Moderate Increased metabolism of Carbamazepine caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [141]
Levamlodipine DM92S6N Major Increased metabolism of Carbamazepine caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [114]
Indapamide DMGN1PW Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Indapamide. Hypertension [BA00-BA04] [171]
Trichlormethiazide DMHAQCO Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Trichlormethiazide. Hypertension [BA00-BA04] [171]
Felodipine DMOSW35 Moderate Increased metabolism of Carbamazepine caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [114]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Hydrochlorothiazide. Hypertension [BA00-BA04] [171]
Conivaptan DM1V329 Moderate Decreased metabolism of Carbamazepine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [189]
Tolvaptan DMIWFRL Major Increased metabolism of Carbamazepine caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [102]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Carbamazepine caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [142]
Pirfenidone DM6VZFQ Moderate Increased metabolism of Carbamazepine caused by Pirfenidone mediated induction of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [102]
Vitamin B3 DMQVRZH Minor Decreased metabolism of Carbamazepine caused by Vitamin B3 mediated inhibition of CYP450 enzyme. Inborn lipid metabolism error [5C52] [106]
Febuxostat DMDEXQ0 Minor Increased metabolism of Carbamazepine caused by Febuxostat mediated induction of UGT. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [102]
Probenecid DMMFWOJ Minor Increased metabolism of Carbamazepine caused by Probenecid mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [190]
Lesinurad DMUR64T Moderate Increased metabolism of Carbamazepine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [191]
TP-434 DM5A31S Major Increased metabolism of Carbamazepine caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [192]
Suvorexant DM0E6S3 Major Increased metabolism of Carbamazepine caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [193]
Amobarbital DM0GQ8N Minor Increased metabolism of Carbamazepine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [103]
Ramelteon DM7IW9J Moderate Increased metabolism of Carbamazepine caused by Ramelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [194]
Flurazepam DMAL4G0 Moderate Increased metabolism of Carbamazepine caused by Flurazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [117]
Triazolam DMETYK5 Moderate Increased metabolism of Carbamazepine caused by Triazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [117]
Zaleplon DMGFWSM Moderate Increased metabolism of Carbamazepine caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [195]
Melatonin DMKWFBT Minor Increased metabolism of Carbamazepine caused by Melatonin mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [129]
Tasimelteon DMLOQ1V Major Increased metabolism of Carbamazepine caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [196]
ITI-007 DMUQ1DO Major Increased metabolism of Carbamazepine caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [197]
Quazepam DMY4D87 Moderate Increased metabolism of Carbamazepine caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [117]
Estazolam DMZGXUM Moderate Increased metabolism of Carbamazepine caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [117]
Naloxegol DML0B41 Major Increased metabolism of Carbamazepine caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [102]
Pemigatinib DM819JF Major Increased metabolism of Carbamazepine caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [102]
Crizotinib DM4F29C Major Increased metabolism of Carbamazepine caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [129]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Carbamazepine and Porfimer Sodium. Lung cancer [2C25] [198]
Ceritinib DMB920Z Major Increased metabolism of Carbamazepine caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [199]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Carbamazepine caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [200]
PF-06463922 DMKM7EW Major Increased metabolism of Carbamazepine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [201]
Osimertinib DMRJLAT Major Increased metabolism of Carbamazepine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [129]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Carbamazepine due to the transporter induction by BIBW 2992. Lung cancer [2C25] [202]
Pralsetinib DMWU0I2 Major Increased metabolism of Carbamazepine caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [203]
Capmatinib DMYCXKL Major Increased metabolism of Carbamazepine caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [204]
Selpercatinib DMZR15V Major Increased metabolism of Carbamazepine caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
Artesunate DMR27C8 Moderate Increased metabolism of Carbamazepine caused by Artesunate mediated induction of UGT. Malaria [1F40-1F45] [205]
Chloroquine DMSI5CB Moderate Increased metabolism of Carbamazepine caused by Chloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [129]
Hydroxychloroquine DMSIVND Moderate Increased metabolism of Carbamazepine caused by Hydroxychloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [129]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Carbamazepine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [206]
Idelalisib DM602WT Major Increased metabolism of Carbamazepine caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [207]
GDC-0199 DMH0QKA Major Increased metabolism of Carbamazepine caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [208]
IPI-145 DMWA24P Major Increased metabolism of Carbamazepine caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [209]
Acalabrutinib DM7GCVW Major Increased metabolism of Carbamazepine caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [210]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Carbamazepine and Clofarabine. Mature B-cell lymphoma [2A85] [211]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Carbamazepine caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [212]
Ibrutinib DMHZCPO Major Increased metabolism of Carbamazepine caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [102]
Ponatinib DMYGJQO Moderate Increased metabolism of Carbamazepine caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [129]
Arry-162 DM1P6FR Moderate Increased metabolism of Carbamazepine caused by Arry-162 mediated induction of UGT. Melanoma [2C30] [129]
Vemurafenib DM62UG5 Major Increased metabolism of Carbamazepine caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [129]
Selumetinib DMC7W6R Major Increased metabolism of Carbamazepine caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [213]
LGX818 DMNQXV8 Major Increased metabolism of Carbamazepine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [214]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Carbamazepine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [129]
Estrone DM5T6US Moderate Increased metabolism of Carbamazepine caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [132]
Ethinyl estradiol DMODJ40 Major Increased metabolism of Carbamazepine caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [150]
Danazol DML8KTN Moderate Decreased metabolism of Carbamazepine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [215]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Carbamazepine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [216]
Ubrogepant DM749I3 Major Increased metabolism of Carbamazepine caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [217]
Rimegepant DMHOAUG Major Increased metabolism of Carbamazepine caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [218]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Carbamazepine and Lasmiditan. Migraine [8A80] [219]
Exjade DMHPRWG Moderate Increased metabolism of Carbamazepine caused by Exjade mediated induction of UGT. Mineral absorption/transport disorder [5C64] [129]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Carbamazepine caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [141]
Flibanserin DM70DTN Major Increased metabolism of Carbamazepine caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [220]
Midazolam DMXOELT Moderate Increased metabolism of Carbamazepine caused by Midazolam mediated induction of CYP450 enzyme. Mood/affect symptom [MB24] [117]
Panobinostat DM58WKG Major Increased metabolism of Carbamazepine caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [221]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Carbamazepine and Thalidomide. Multiple myeloma [2A83] [222]
Siponimod DM2R86O Major Increased metabolism of Carbamazepine caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [129]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Carbamazepine and Ocrelizumab. Multiple sclerosis [8A40] [223]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Carbamazepine and Ozanimod. Multiple sclerosis [8A40] [224]
Deflazacort DMV0RNS Major Increased metabolism of Carbamazepine caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [102]
Rifabutin DM1YBHK Moderate Increased metabolism of Carbamazepine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [103]
Romidepsin DMT5GNL Moderate Increased metabolism of Carbamazepine caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [225]
Fedratinib DM4ZBK6 Major Increased metabolism of Carbamazepine caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [102]
Nilotinib DM7HXWT Major Increased metabolism of Carbamazepine caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [226]
Imatinib DM7RJXL Major Increased metabolism of Carbamazepine caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [227]
Dasatinib DMJV2EK Major Increased metabolism of Carbamazepine caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [129]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Carbamazepine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [228]
Vorapaxar DMA16BR Major Increased metabolism of Carbamazepine caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [229]
Modafinil DMYILBE Moderate Increased metabolism of Carbamazepine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [129]
Rolapitant DM8XP26 Major Increased metabolism of Carbamazepine caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [102]
Netupitant DMEKAYI Major Increased metabolism of Carbamazepine caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [129]
Ondansetron DMOTQ1I Moderate Increased metabolism of Carbamazepine caused by Ondansetron mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [102]
E-2007 DMJDYNQ Moderate Increased metabolism of Carbamazepine caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [102]
Bupropion DM5PCS7 Moderate Increased metabolism of Carbamazepine caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [129]
Entrectinib DMMPTLH Major Increased metabolism of Carbamazepine caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [230]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Carbamazepine and Polythiazide. Oedema [MG29] [171]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Carbamazepine caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [231]
S-297995 DM26IH8 Major Increased metabolism of Carbamazepine caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [232]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Carbamazepine and Apraclonidine. Optic nerve disorder [9C40] [233]
Valdecoxib DMAY7H4 Moderate Increased metabolism of Carbamazepine caused by Valdecoxib mediated induction of CYP450 enzyme. Osteoarthritis [FA00-FA05] [234]
Diclofenac DMPIHLS Moderate Increased metabolism of Carbamazepine caused by Diclofenac mediated induction of CYP450 enzyme. Osteoarthritis [FA00-FA05] [129]
Olaparib DM8QB1D Major Increased metabolism of Carbamazepine caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [129]
Rucaparib DM9PVX8 Moderate Increased metabolism of Carbamazepine caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [235]
MK-4827 DMLYGH4 Moderate Accelerated clearance of Carbamazepine due to the transporter induction by MK-4827. Ovarian cancer [2C73] [236]
Dextropropoxyphene DM23HCX Major Decreased metabolism of Carbamazepine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [237]
Butorphanol DM5KYPJ Major Increased metabolism of Carbamazepine caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [129]
Hydrocodone DMQ2JO5 Major Increased metabolism of Carbamazepine caused by Hydrocodone mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [129]
Istradefylline DM20VSK Major Increased metabolism of Carbamazepine caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [238]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Carbamazepine and Rasagiline. Parkinsonism [8A00] [107]
Pimavanserin DMR7IVC Moderate Increased metabolism of Carbamazepine caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [239]
Abametapir DM2RX0I Moderate Decreased metabolism of Carbamazepine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [240]
Lefamulin DME6G97 Major Accelerated clearance of Carbamazepine due to the transporter induction by Lefamulin. Pneumonia [CA40] [241]
Prednisone DM2HG4X Moderate Increased metabolism of Carbamazepine caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [142]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Carbamazepine caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [142]
Ergonovine DM0VEC1 Moderate Increased metabolism of Carbamazepine caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [129]
Lonafarnib DMGM2Z6 Major Increased metabolism of Carbamazepine caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [242]
ABIRATERONE DM8V75C Major Increased metabolism of Carbamazepine caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [243]
Relugolix DMK7IWL Major Increased metabolism of Carbamazepine caused by Relugolix mediated induction of CYP450 enzyme. Prostate cancer [2C82] [244]
Darolutamide DMV7YFT Major Increased metabolism of Carbamazepine caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [245]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Carbamazepine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [102]
Apremilast DMTWS9E Major Increased metabolism of Carbamazepine caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [246]
Ixekizumab DMXW92T Moderate Altered metabolism of Carbamazepine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [102]
Riociguat DMXBLMP Moderate Increased metabolism of Carbamazepine caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [247]
Everolimus DM8X2EH Major Increased metabolism of Carbamazepine caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [118]
Axitinib DMGVH6N Major Increased metabolism of Carbamazepine caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [248]
Temsirolimus DMS104F Major Increased metabolism of Carbamazepine caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [129]
Upadacitinib DM32B5U Major Increased metabolism of Carbamazepine caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [249]
Tocilizumab DM7J6OR Moderate Altered metabolism of Carbamazepine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [102]
Canakinumab DM8HLO5 Moderate Altered metabolism of Carbamazepine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [102]
Tofacitinib DMBS370 Major Increased metabolism of Carbamazepine caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [129]
Rilonacept DMGLUQS Moderate Altered metabolism of Carbamazepine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [102]
Golimumab DMHZV7X Moderate Altered metabolism of Carbamazepine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [102]
Dexamethasone DMMWZET Moderate Increased metabolism of Carbamazepine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [142]
Sarilumab DMOGNXY Moderate Altered metabolism of Carbamazepine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [102]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Carbamazepine and Leflunomide. Rheumatoid arthritis [FA20] [118]
Quetiapine DM1N62C Major Increased metabolism of Carbamazepine caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [129]
Aripiprazole DM3NUMH Moderate Increased metabolism of Carbamazepine caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [250]
Paliperidone DM7NPJS Moderate Accelerated clearance of Carbamazepine due to the transporter induction by Paliperidone. Schizophrenia [6A20] [129]
Thiothixene DMDINC4 Moderate Increased metabolism of Carbamazepine caused by Thiothixene mediated induction of CYP450 enzyme. Schizophrenia [6A20] [251]
Fentanyl DM8WAHT Major Increased metabolism of Carbamazepine caused by Fentanyl mediated induction of CYP450 enzyme. Sensation disturbance [MB40] [129]
Avanafil DM75CXN Moderate Increased metabolism of Carbamazepine caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [252]
Tadalafil DMJZHT1 Moderate Increased metabolism of Carbamazepine caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [102]
Voxelotor DMCS6M5 Major Increased metabolism of Carbamazepine caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [253]
LDE225 DMM9F25 Major Increased metabolism of Carbamazepine caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [254]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Carbamazepine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [102]
Larotrectinib DM26CQR Major Accelerated clearance of Carbamazepine due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [129]
Methylprednisolone DM4BDON Moderate Increased metabolism of Carbamazepine caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [142]
Vinblastine DM5TVS3 Moderate Increased metabolism of Carbamazepine caused by Vinblastine mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [255]
Docetaxel DMDI269 Moderate Increased metabolism of Carbamazepine caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [256]
Trabectedin DMG3Y89 Major Increased metabolism of Carbamazepine caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [102]
Armodafinil DMGB035 Moderate Increased metabolism of Carbamazepine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [129]
LEE011 DMMX75K Major Decreased metabolism of Carbamazepine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [257]
Etoposide DMNH3PG Moderate Increased metabolism of Carbamazepine caused by Etoposide mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [258]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Carbamazepine caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [142]
Vandetanib DMRICNP Moderate Increased metabolism of Carbamazepine caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [259]
Norethindrone DMTY169 Major Increased metabolism of Carbamazepine caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [150]
Taxol DMUOT9V Moderate Increased metabolism of Carbamazepine caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [260]
Pitolisant DM8RFNJ Major Increased metabolism of Carbamazepine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [102]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Carbamazepine and Naltrexone. Substance abuse [6C40] [261]
Warfarin DMJYCVW Moderate Increased metabolism of Carbamazepine caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [145]
Pomalidomide DMTGBAX Moderate Accelerated clearance of Carbamazepine due to the transporter induction by Pomalidomide. Systemic sclerosis [4A42] [262]
Fostamatinib DM6AUHV Major Increased metabolism of Carbamazepine caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [263]
As-1670542 DMV05SW Major Increased metabolism of Carbamazepine caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [264]
Apixaban DM89JLN Major Accelerated clearance of Carbamazepine due to the transporter induction by Apixaban. Thrombosis [DB61-GB90] [102]
Brilinta DMBR01X Major Increased metabolism of Carbamazepine caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [265]
Cabozantinib DMIYDT4 Major Increased metabolism of Carbamazepine caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [266]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Carbamazepine and Tizanidine. Tonus and reflex abnormality [MB47] [267]
Sirolimus DMGW1ID Major Accelerated clearance of Carbamazepine due to the transporter induction by Sirolimus. Transplant rejection [NE84] [129]
Tacrolimus DMZ7XNQ Major Increased metabolism of Carbamazepine caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [268]
Canagliflozin DMFRM1I Moderate Increased metabolism of Carbamazepine caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [129]
Linagliptin DMWFJTR Moderate Increased metabolism of Carbamazepine caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [269]
Elagolix DMB2C0E Moderate Increased metabolism of Carbamazepine caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [270]
Triamcinolone DM98IXF Moderate Increased metabolism of Carbamazepine caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [142]
Betrixaban DM2C4RF Moderate Accelerated clearance of Carbamazepine due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [271]
Amiodarone DMUTEX3 Major Increased metabolism of Carbamazepine caused by Amiodarone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [272]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Carbamazepine and Ganciclovir. Virus infection [1A24-1D9Z] [129]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Carbamazepine and Valganciclovir. Virus infection [1A24-1D9Z] [129]
⏷ Show the Full List of 311 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Oleic acid E00421 445639 Emulsifying agent; Penetration agent; Solubilizing agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Potassium sorbate E00566 23676745 Antimicrobial preservative
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate E00395 110800 Emollient; Opacifying agent; Surfactant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Sorbitan monolaurate E00508 11046239 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Sucrose 1,6-distearate E00593 71587490 Dispersing agent; Emulsifying agent; Modified-release agent; Solubilizing agent; Surfactant; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
⏷ Show the Full List of 37 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Carbamazepine 100 mg capsule 100 mg 12 HR Extended Release Oral Capsule Oral
Carbamazepine 200 mg capsule 200 mg 12 HR Extended Release Oral Capsule Oral
Carbamazepine 200 mg tablet 200 mg Chewable Tablet Oral
Carbamazepine 300 mg capsule 300 mg 12 HR Extended Release Oral Capsule Oral
Carbamazepine 100 mg tablet 100 mg Chewable Tablet Oral
Carbamazepine 200 mg tablet 200 mg 12 HR Extended Release Oral Tablet Oral
Carbamazepine 200 mg tablet 200 mg 12 HR Extended Release Tablet Oral
Carbamazepine 100 mg tablet 100 mg 12 HR Extended Release Oral Tablet Oral
Carbamazepine 400 mg tablet 400 mg 12 HR Extended Release Oral Tablet Oral
Carbamazepine 400 mg tablet 400 mg 12 HR Extended Release Tablet Oral
Carbamazepine 100 mg tablet 100 mg Oral Tablet Oral
Carbamazepine 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5339).
2 Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice. CNS Drugs. 2007;21(1):47-71.
3 Clinical pipeline report, company report or official report of Lundbeck.
4 ClinicalTrials.gov (NCT01128959) Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy. U.S. National Institutes of Health.
5 Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR: A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013 Mar;18(Suppl 1):S81-5.
6 BDDCS applied to over 900 drugs
7 FDA Approved Drug Products: EQUETRO (carbamazepine) extended-release capsules
8 Matsushima H, Kamimura H, Soeishi Y, Watanabe T, Higuchi S, Tsunoo M: Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs, and humans. Drug Metab Dispos. 1998 Mar;26(3):240-5.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, Ramsay RE, Pennell PB, White JR, Gross CR, Rarick JO, Mishra U, Cloyd JC: Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012 Mar;91(3):483-8. doi: 10.1038/clpt.2011.251. Epub 2012 Jan 25.
11 Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
12 A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
13 Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
14 Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311-34.
15 Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
16 Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58.
17 Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul;20(7):851-4.
18 CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos. 2003 Apr;31(4):432-8.
19 Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45.
20 Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol. 2005 Mar;61(1):25-34.
21 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
22 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
23 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
24 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
25 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
26 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
27 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
28 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
29 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
30 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
31 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
32 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
33 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
34 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
35 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
36 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
37 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
38 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
39 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
40 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
41 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
42 Drug Interactions Flockhart Table
43 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
44 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
45 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
46 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
47 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
48 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
49 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
50 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
51 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
52 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
53 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
54 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
55 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
56 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
57 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
58 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
59 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
60 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
61 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
62 Drugs that may have potential CYP2B6 interactions.
63 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
64 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
65 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
66 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
67 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
68 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
69 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
70 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
71 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
72 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
73 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
74 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
75 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
76 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
77 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
78 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
79 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
80 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
81 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
82 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
83 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
84 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
85 Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
86 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
87 Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
88 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
89 Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
90 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
91 In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
92 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
93 WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
94 Battino D, Avanzini G, Bossi L, Croci D, Cusi C, Gomeni C, Moise A "Plasma levels of primidone and its metabolite phenobarbital: effect of age and associated therapy." Ther Drug Monit 5 (1983): 73-9. [PMID: 6845402]
95 Albani F, Theodore WH, Washington P, Devinsky O, Bromfield E, Porter RJ, Nice FJ "Effect of felbamate on plasma levels of carbamazepine and its metabolites." Epilepsia 32 (1991): 130-2. [PMID: 1985822]
96 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
97 Giaccone M, Bartoli A, Gatti G, Marchiselli R, Pisani F, Latella MA, Perucca E "Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients." Br J Clin Pharmacol 41 (1996): 575-9. [PMID: 8799524]
98 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
99 Product Information. Gabitril (tiagabine). Abbott Pharmaceutical, Abbott Park, IL.
100 Cazali N, Tran A, Treluyer JM, et al. "Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human." Br J Clin Pharmacol 56 (2003): 526-36. [PMID: 14651727]
101 Gratz ES, Theodore WH, Newmark ME, Kupferberg HJ, Porter RJ, Qu Z "Effect of carbamazepine on phenytoin clearance in patients with complex partial seizures." Neurology 32 (1982): a223.
102 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
103 Benetello P, Furlanut M "Primidone-carbamazepine interaction: clinical consequences." Int J Clin Pharmacol Res 7 (1987): 165-8. [PMID: 3583497]
104 Bialer M, Soares-da-Silva P "Pharmacokinetics and drug interactions of eslicarbazepine acetate." Epilepsia 53 (2012): 935-46. [PMID: 22612290]
105 Bernard A, Kermarrec G, Parize P, et.al "Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination." J Infect 71 (2015): 200-6. [PMID: 25936632]
106 Bourgeois BF, Dodson WE, Ferrendellis JA "Interactions between primidone, carbamazepine, and nicotinamide." Neurology 32 (1982): 1122-6. [PMID: 6214728]
107 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
108 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
109 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
110 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
111 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
112 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
113 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
114 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
115 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
116 Cereghino JJ, Brock JT, Van Meter JC, et al "The efficacy of carbamazepine combinations in epilepsy." Clin Pharmacol Ther 18 (1975): 733-41. [PMID: 1106934]
117 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
118 Canadian Pharmacists Association.
119 Mitchell EA "Interaction between carbamazinepine and theophylline." N Z Med J 1 (1986): 69-70. [PMID: 3080715]
120 Nassr N, Huennemeyer A, Herzog R, et al. "Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects." Br J Clin Pharmacol 68 (2009): 580-7. [PMID: 19843061]
121 Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
122 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
123 Albani F, Riva R, Baruzzi A "Clarithromycin-carbamazepine interaction: a case report." Epilepsia 34 (1993): 161-2. [PMID: 8422851]
124 Product Information. Potiga (ezogabine). GlaxoSmithKline, Research Triangle Park, NC.
125 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
126 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
127 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
128 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
129 Cerner Multum, Inc. "Australian Product Information.".
130 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
131 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
132 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
133 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
134 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
135 Chang TK, Yu L, Maurel P, Waxman DJ "Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines." Cancer Res 57 (1997): 1946-54. [PMID: 9157990]
136 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
137 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
138 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
139 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
140 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
141 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
142 Keitner GI, Fruzzetti AE, Miller IW, Norman WH, Brown WA "The effect of anticonvulsants on the dexamethasone suppression test." Can J Psychiatry 34 (1989): 441-3. [PMID: 2766197]
143 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
144 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
145 Denbow CE, Frazer HS "Clinically significant hemorrhage due to warfarin-carbamazepine interaction." South Med J 83 (1990): 981. [PMID: 2382161]
146 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
147 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
148 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
149 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
150 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
151 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
152 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
153 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
154 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
155 Ashton AK, Wolin RE "Nefazodone-induced carbamazepine toxicity." Am J Psychiatry 153 (1996): 733. [PMID: 8615427]
156 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
157 Moller SE, Larsen F, Khant AZ, Rolan PE "Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects." J Clin Psychopharmacol 21 (2001): 493-9. [PMID: 11593075]
158 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
159 Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, Sugawara K "Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine." Ther Drug Monit 18 (1996): 164-7. [PMID: 8721280]
160 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
161 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
162 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
163 Product Information. Carbatrol (carbamazepine). Athena Neurosciences Inc, South San Francisco, CA.
164 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
165 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
166 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
167 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
168 Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97. [PMID: 9512916]
169 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
170 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
171 Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
172 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
173 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
174 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
175 Barbare JC, Lallement PY, Vorhauer W, Veyssier P "Hepatotoxicity of isoniazide: influence of carbamazepine?" Gastroenterol Clin Biol 10 (1986): 523. [PMID: 3758598]
176 Ramsay RE, McManus DQ, Guterman A, et al "Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy." Ther Drug Monit 12 (1990): 235-41. [PMID: 2112276]
177 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
178 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
179 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
180 Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA "Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients." Antiviral Res 35 (1997): 53-63. [PMID: 9224961]
181 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
182 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
183 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
184 Bates DE, Herman RJ "Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir." Ann Pharmacother 40 (2006): 1190-5. [PMID: 16720703]
185 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
186 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
187 Product Information. Crestor (rosuvastatin). AstraZeneca Pharma Inc, Mississauga, ON.
188 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
189 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
190 Kim KA, Oh SO, Park PW, Park JY "Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects." Eur J Clin Pharmacol 61 (2005): 275-80. [PMID: 15915352]
191 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
192 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
193 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
194 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
195 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
196 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
197 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
198 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
199 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
200 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
201 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
202 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
203 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
204 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
205 Product Information. Artesunate (artesunate). Amivas, Frederick, MD.
206 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
207 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
208 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
209 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
210 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
211 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
212 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
213 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
214 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
215 Kramer G, Theisohn M, von Unruh GE, Eichelbaum M "Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique." Ther Drug Monit 8 (1986): 387-92. [PMID: 3824425]
216 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
217 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
218 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
219 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
220 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
221 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
222 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
223 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
224 de la Fuente JR, Berlanga C, Leon-Andrade C "Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports." J Clin Psychiatry 47 (1986): 40-1. [PMID: 3941059]
225 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
226 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
227 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
228 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
229 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
230 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
231 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
232 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
233 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
234 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
235 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
236 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
237 Allen S "Cerebellar dysfunction following dextropropoxyphene-induced carbamazepine toxicity." Postgrad Med J 70 (1994): 764. [PMID: 7831181]
238 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
239 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
240 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
241 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
242 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
243 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
244 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
245 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
246 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
247 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
248 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
249 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
250 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
251 Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW "Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables." J Clin Psychopharmacol 11 (1991): 296-301. [PMID: 1765572]
252 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
253 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
254 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
255 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
256 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
257 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
258 Rodman JH, Murry DJ, Madden T, Santana VM "Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation." J Clin Oncol 12 (1994): 2390-7. [PMID: 7964955]
259 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
260 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
261 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
262 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
263 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
264 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
265 Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
266 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
267 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
268 Bhaloo S, Prasad GV "Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report." Transplant Proc 35 (2003): 2449-51. [PMID: 14611983]
269 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
270 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
271 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]
272 Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.